Preventing a Second Cancer After Your First Cancer
Treatments studied
Part of Cancer clinical trials.
This Phase 2 trial tests dostarlimab, an immune-based medicine, to help lower the chance of getting a second (new) cancer after treatment for a first solid tumor. It’s for people with higher risk features, and it aims to see whether the drug can prevent or delay second cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older (or have a qualifying childhood first cancer).
- You had a solid tumor cancer before that was proven by pathology and was treated with curative intent, and randomization must be within 6 months after finishing that treatment.
- You have at least one higher-risk feature for a second cancer, such as long-term smoking or a known genetic risk, or HPV-related first cancer.
- You can provide stored tumor tissue from your first cancer (FFPE sample) from the time of your first diagnosis, for side-by-side comparison.
- Your blood counts and organs (kidneys, liver, blood clotting) are in acceptable ranges on screening blood/urine tests.
- You must not have certain conditions that increase risk with immune medicines (for example, prior immunotherapy for the first cured cancer, active infections like hepatitis B/C or HIV, or autoimmune disease).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether using special computer software and expert input can safely give a second round of radiation to treat cancers that have come back or spread in a limited way. It aims to offer a chance for cure when standard treatments may not work.
This study tests giving a second round of radiation therapy to women whose breast cancer has come back in the same breast, at least 3 years after their first radiation. It may be an option for women 55 and older who have a small, local recurrence that can be removed with surgery.
This trial tests whether having a second surgery after initial treatment can help people with ovarian cancer that came back but still responds to platinum-based chemotherapy. It may offer another option to remove remaining tumors and delay further treatments.
This trial tests a focused radiation treatment for patients who have developed a new cancer in the same breast after previous breast-conserving therapy. The goal is to safely treat the cancer while minimizing radiation to surrounding healthy tissue.
This trial tests whether giving immunotherapy again can help people with solid tumors who have already tried an experimental treatment in a clinical trial and it stopped working. It looks for patients whose cancer has returned or spread and who can start the new treatment within 12 weeks of their last therapy.
This study looks back at patients with advanced stomach cancer who received immunotherapy again as a second treatment. It aims to understand if giving the same type of immune-boosting drug a second time can help people who already got it as their first therapy.
Hear when a new Recurrent Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.